Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Assessing the Symptoms of Obstructive Sleep Apnea (OSA)

maanantai 16. kesäkuuta 2014 päivittänyt: Bangor University

Association of Health Outcomes With Severity of OSA Symptomatology- a Correlation Study.

The purpose of this study is to investigate the correlation between health outcomes associated with the severity of obstructive sleep apnea (OSA) symptomatology, the findings will guide the design of interventional studies.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Yksityiskohtainen kuvaus

Obstructive sleep apnea is a condition characterised by periods of narrowing of the pharyngeal airways during sleep causing hypoxic and hypercapnic episodes with the cessation of ventilation. Considering the high number of overweight and obese individuals in Western society the understanding of the pathomechanisms behind OSA are important. This observational study aims to investigate the correlations between the severity of Obstructive Sleep Apnea assessed by the apnea-hypopnea index (AHI) and different health outcomes associated with the OSA.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Todellinen)

66

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Yhdistynyt kuningaskunta
    • Gwynedd
      • Bangor, Gwynedd, Yhdistynyt kuningaskunta, LL57 2PW
        • Betsi Cadwaladr University Health Board

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 70 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Uros

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

Mild to severe recently diagnosed Obstructive Sleep Apnea patients selected by physician who have not received any treatment for their condition. Selected from Ysbyty Gwynedd in North Wales.

Kuvaus

Inclusion Criteria:

  • Body Mass Index ≤39
  • Not received any treatment for Obstructive Sleep Apnea.
  • Is a non-smoker
  • Is not epileptic
  • Epworth Sleepiness Scale ≥ 10.
  • Patient's on Statins or antihypertensive drugs are included as so frequent in OSA.

Exclusion Criteria:

  • Body Mass Index ≥ 39.
  • Presence of significant or unstable Renal, Liver or Heart Failure.
  • Receiving anti-diabetic treatment.
  • Is a smoker.
  • Is epileptic
  • Presence of significant or unstable psychological morbidities.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Kohortit ja interventiot

Ryhmä/Kohortti
No treatment, OSA (AHI >15)
Patients with OSA recruited prior to receiving NHS treatment.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Apnea-Hypopnea Index (AHI)
Aikaikkuna: one night within four weeks of study.
AHI refers to how is the number of apneas and hypopneas per an hour of sleep.
one night within four weeks of study.

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Residual volume
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Volume of air remaining in lungs after full expiration
Within four weeks of recruitment prior to CPAP treatment
Functional residual volume
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Air present in lungs at the end of passive expiration
Within four weeks of recruitment prior to CPAP treatment
Total lung capacity
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Total volume of lungs
Within four weeks of recruitment prior to CPAP treatment
Forced Vital capacity
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Maximum amount of air which can be expired from the lungs following a full inspiration
Within four weeks of recruitment prior to CPAP treatment
Forced expiratory volume in one second (FEV1)
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Maximum amount of air which can be expired from the lungs in one second.
Within four weeks of recruitment prior to CPAP treatment
Airway Resistance
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Opposition of flow caused by forces of friction.
Within four weeks of recruitment prior to CPAP treatment
Plasma 2-arachidonoylglycerol (2-AG)
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment.
Ligand of the G-protein coupled CB1 and CB2 receptors, has been found to be correlated with Oleylethanolamide (OEA) in OSA patients have various effects on energy metabolism.
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment.
Plasma Anandamide (ANA)
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
Ligand of the G-protein coupled CB1 and CB2 receptors, found to be correlated with blood pressure in OSA after the adjustment of confounding variables. Have various effects on energy metabolism.
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
Plasma oleoylethanolamine (OEA)
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
A lipid mediator which acts as an anorexigenic (appetite suppressant), and is elevated with sleep deprivation.
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
Plasma Leptin
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
Circulating protein produced in adipose tissue. Elevated in OSA and obesity. Leptin may reduce respiratory depression.
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
Plasma Adiponectin
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
Hormone secreted by adipocytes (Fat cells). Adiponectin is closely linked to metabolism and may have anti-inflammatory properties.
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
Plasma C-reactive Protein
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
Marker of inflammation.
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
Insulin
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
Hormone which causes liver and muscle and fat cells to take up glucose to convert to glycogen. OSA is associated with insulin resistance.
Within four weeks of recruitment prior to CPAP treatment and after four weeks of CPAP treatment
Neck circumference
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Within four weeks of recruitment prior to CPAP treatment
Waist circumference
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Within four weeks of recruitment prior to CPAP treatment
Hip circumference
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Within four weeks of recruitment prior to CPAP treatment
Weight
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Within four weeks of recruitment prior to CPAP treatment
Fat-free mass
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Non-fat components of the human body estimated non-invasively using a bioimpedance measurement system.
Within four weeks of recruitment prior to CPAP treatment
Fat mass
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Fat components of the human body estimated non-invasively using bioimpedance measurement system.
Within four weeks of recruitment prior to CPAP treatment
Maximal Inspiratory pressure
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Measured at residual volume, reflects the strength of the diaphragm and other inspiratory muscles.
Within four weeks of recruitment prior to CPAP treatment
Rate of inspiratory muscle fatigue
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
The decline in maximal inspiratory pressure following inspiration against a resistance.
Within four weeks of recruitment prior to CPAP treatment
Chest RPE
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Rating of perceived exertion in the chest and associated airways during the inspiratory fatigue protocol.
Within four weeks of recruitment prior to CPAP treatment
Dyspnea
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Rating of breathlessness half way through fatigue protocol and at the end of protocol.
Within four weeks of recruitment prior to CPAP treatment
Ventilation with 25% O2/ 6% CO2
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Measures the breathing response to high oxygen and high CO2 therefore assessing the central chemoreceptors response only.
Within four weeks of recruitment prior to CPAP treatment
Ventilation with 13% O2
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Measures the breathing response to low oxygen. Designed to Assess the response to the peripheral chemoreceptors.
Within four weeks of recruitment prior to CPAP treatment
Ventilation with 13% O2 / 6% CO2
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Measures the breathing response to low oxygen and high CO2. Designed to assess the response of the sum of the peripheral and central chemoreceptors
Within four weeks of recruitment prior to CPAP treatment
Mean RR interval
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Time domain measure: Average time interval between the heart beats R waves
Within four weeks of recruitment prior to CPAP treatment
SDNN
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Time domain measure: The standard deviation of all RR intervals
Within four weeks of recruitment prior to CPAP treatment
NN50 count
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Time domain measure: The number of pairs of adjacent RR intervals differing by more than 50 ms in the entire analysis interval.
Within four weeks of recruitment prior to CPAP treatment
NN50 of total HR (%)
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
Time domain measure: NN50 count divided by total number of all RR intervals.
Within four weeks of recruitment prior to CPAP treatment
HRV triangular index
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment
The total number of RR intervals divided by maximum height of the histogram excluding boundaries.
Within four weeks of recruitment prior to CPAP treatment
Low frequency domain
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment.
Frequency domain analysis: represents 0.04-0.15 Hz reflecting sympathetic activity.
Within four weeks of recruitment prior to CPAP treatment.
High frequency domain
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment.
Frequency domain analysis: represents 0.15-0.40 Hz reflecting parasympathetic activity.
Within four weeks of recruitment prior to CPAP treatment.
LF/HF ratio
Aikaikkuna: Within four weeks of recruitment prior to CPAP treatment.
The ratio of low frequency (0.04 - 0.15 Hz) to high (0.15-0.40 Hz) frequency recordings.
Within four weeks of recruitment prior to CPAP treatment.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Bangor University

Tutkijat

  • Päätutkija: Christopher MN Earing, MSc, School of Sport, Health and Exercise Sciences, Bangor University

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus

Tiistai 1. marraskuuta 2011

Ensisijainen valmistuminen (Todellinen)

Sunnuntai 1. kesäkuuta 2014

Opintojen valmistuminen (Todellinen)

Sunnuntai 1. kesäkuuta 2014

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 24. marraskuuta 2011

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 24. marraskuuta 2011

Ensimmäinen Lähetetty (Arvio)

Tiistai 29. marraskuuta 2011

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Arvio)

Tiistai 17. kesäkuuta 2014

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 16. kesäkuuta 2014

Viimeksi vahvistettu

Sunnuntai 1. kesäkuuta 2014

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • REC No: 11/WNo:01/2
  • Earing 11/WNo01/2 (Muu tunniste: North West Wales Research Ethics Committee)

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Kliiniset tutkimukset Obstruktiivinen uniapnea

Hae vastaavia kokeiluja

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

CROs by country

CROs in Belgium

Ehdot

Harvinaiset sairaudet

Huumeiden interventiot

Ravintolisät

Sponsori / yhteistyökumppanit

Sijainnit

3
Tilaa